ASND vs CDNA
Ascendis Pharma A/S vs CareDx, Inc — AI-powered side-by-side comparison
ASND
Ascendis Pharma A/S
66
Buy
VS
| Metric | ASND | CDNA |
|---|
| AI Score |
66
|
59
|
| Price |
$254.27
|
$47.20
|
| P/E Ratio |
26.92×
|
21.95×
|
| ROE |
134.6%
|
-7.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
88.2%
|
70.6%
|
| Debt / Equity |
1.84×
|
0.05×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.3
|
74.3
|
| Beta |
0.382
|
2.419
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ASND versus CDNA.
ASND leads by 7 points.
ASND scores 66/100 (Buy) versus CDNA at 59/100 (Buy).
ASND Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value
CDNA Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 50.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 50.3% signals elevated volatility — Risk